Delcath Systems Inc（DCTH）の株式分析DCTHDelcath Systems Inc

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's proprietary products, HEPZATO KIT (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATOTM KIT is a drug/device combination product. HEPZATO KIT comprises the chemotherapeutic drug melphalan and the Company’s proprietary Hepatic Delivery System (HDS). In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan. In the United States, HEPZATO is regulated as a drug by the United States Food and Drug Administration (FDA). It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Delcath Systems Inc is a good buy right now due to its recent strong earnings performance and optimistic future outlook. The current price is $16.34, with a forward P/E ratio of 13.57, indicating potential for growth. Additionally, the company has raised its 2026 revenue guidance to between $104 million and $108 million, reflecting confidence in continued revenue growth. The main risk is the high P/E ratio of 1069, which suggests that the stock is currently overvalued based on earnings expectations.